At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 929 enrolled
Drug / intervention
liraglutide +6 moredrug
Likely dose
liraglutide 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating liraglutide, placebo, and 2 other interventions for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 929 participants across 50 sites in 3 countries.
Detailed Summary
This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina, India, South Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedFeb 13, 2008
Enrollment StartJan 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.4 years ago
Interventions
liraglutidedrug
0.6 mg/day, s.c. (under the skin) injection
placebodrug
Glimepiride placebo, capsules
liraglutidedrug
1.2 mg/day, s.c. (under the skin) injection
liraglutidedrug
1.8 mg/day, s.c. (under the skin) injection
glimepiridedrug
Capsules, 4.0 mg/day
metformindrug
Tablets, 1.5-2.0 g/day
placebodrug
Liraglutide placebo, s.c. (under the skin) injection